 |
Can prasinezumab prevent progression?
|
An article originally published in the Ärzteblatt is about the effect of the drug prasinezumab on motor symptoms. In a clinical trial, it was observed that the placebo group experienced a major worsening of their symptoms by 12,29 points. In the group treated with prasinezumab, this deterioration was significantly reduced - to just 4,39 points. This means the drug reduced deterioration by 64%. The difference of 7,89 points between the two groups was statistically significant as it was both greater than the 80% confidence interval of 2,82 to 12,90 points and above the 4,63 point threshold for clinical relevance .
However, Pagano emphasizes that the results come from a retrospective analysis of a phase 2 study that was initially considered a failure and therefore do not provide definitive evidence. To truly ensure the effectiveness of prasinezumab, it is recommended that another study be conducted.
Another study called PADOVA is currently investigating whether prasinezumab in combination with other treatments such as MAO-B inhibitors or L-dopa can delay the worsening of motor symptoms. The first results of this study are expected this year.
Summary
| feature | Description |
| Study name | Not specified, but reference to a phase 2 study |
| drug | Prasinezumab |
| Placebo worsening | 12,29 points |
| Improvement with prasinezumab | Reduced to 4,39 points (64% improvement) |
| Statistical significance | Yes, with a confidence interval of 2,82 to 12,90 points |
| Clinical Relevance | Above the threshold of 4,63 points |
| Suggestions | Further study needed for definitive evidence |
| Ongoing study | PADOVA study |
| expected results | Still this year |
Jurgen Zender, August 29.04.2024, XNUMX
Leave a comment
Participate in the discussion?Leave us your comment!